Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.
American Journal of Psychiatry May 18, 2022 H. Tabuteau, A. Jones, Ashley Anderson et al.
In a randomized trial, the combination drug dextromethorphan-bupropion (AXS-05) improved depressive symptoms more than bupropion alone in adults with moderate-to-severe major depressive disorder. Over six weeks, the average reduction in depression scores was 13.7 points with the combination versus 8.8 points with bupropion. By week six, 46.5% of those taking the combination achieved remission, compared to 16.2% taking bupropion. The combination was generally well tolerated, with common side effects including dizziness, nausea, and dry mouth, and was not linked to weight gain or sexual dysfunction.